Dr Lal PathLabs is acquiring a 70% stake in SN Genelab for approximately Rs 168 crore. The deal aims to strengthen its genomics and diagnostic service offerings. The transaction is expected to finalize by November 30, 2026.
Dr. Lal PathLabs acquires a 70% stake in SN Genelab for up to ₹168 crore in cash. The deal aims to bolster the company’s genomics capabilities. Completion of the acquisition is expected by November 30, 2026.
Dr Lal PathLabs resumes its acquisition strategy after a three-year consolidation period. The company targets strategic deals to expand its presence in South India, addressing gaps in its current service footprint. The move follows its recent integration of a major acquisition.
Dr Lal Pathlabs reports a **16.56% year-over-year increase in net profit** and a **10.66% revenue growth** for Q2 FY26. The company’s profit after tax (PAT) reaches **Rs 150.60 crore**, while total revenue hits **Rs 730.60 crore**. These figures reflect strong financial performance in diagnostics and pathology services.
